Regeneron Pharmaceuticals (REGN) Accounts Payables (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Accounts Payables of $1.2 billion for Q2 2026, up 60.15% year-over-year from $723.9 million in Q2 2025, and up 12.87% quarter-over-quarter from $1.0 billion in Q1 2026.
Regeneron Pharmaceuticals (REGN) Accounts Payables (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Accounts Payables history runs 18 years deep, the most recent figure standing at $1.2 billion for Q2 2026.
- In Q2 2026, Accounts Payables rose 60.15% year-over-year to $1.2 billion; the TTM figure through Jun 2026 stood at $1.2 billion (up 60.15% YoY), while the FY2025 annual figure was $939.0 million, up 18.94% from the prior year.
- Accounts Payables for Q2 2026 stood at $1.2 billion, up from $1.0 billion in the prior quarter.
- The five-year high for Accounts Payables was $1.2 billion in Q2 2026, with the low at $470.3 million in Q1 2022.
- The 5-year median for Accounts Payables is $603.0 million (2023), against an average of $688.8 million.
- The sharpest annual moves came in 2022 and 2025: Accounts Payables fell 13.37% in 2022, then jumped 81.74% in 2025.
- Regeneron Pharmaceuticals' Accounts Payables stood at $589.2 million in 2022, then advanced by 2.95% to $606.6 million in 2023, then soared by 30.15% to $789.5 million in 2024, then advanced by 18.94% to $939.0 million in 2025, then gained by 23.46% to $1.2 billion in 2026.
- Business Quant data shows REGN's Accounts Payables at $1.2 billion in Q2 2026, $1.0 billion in Q1 2026, and $939.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 25.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.16 Bn |
| Mar 31, 2026 | 1.03 Bn |
| Dec 31, 2025 | 939.00 Mn |
| Sep 30, 2025 | 903.80 Mn |
| Jun 30, 2025 | 723.90 Mn |
| Mar 31, 2025 | 705.50 Mn |
| Dec 31, 2024 | 789.50 Mn |
| Sep 30, 2024 | 497.30 Mn |
| Jun 30, 2024 | 561.70 Mn |
| Mar 31, 2024 | 671.30 Mn |
| Dec 31, 2023 | 606.60 Mn |
| Sep 30, 2023 | 536.60 Mn |
| Jun 30, 2023 | 547.30 Mn |
| Mar 31, 2023 | 599.50 Mn |
| Dec 31, 2022 | 589.20 Mn |
| Sep 30, 2022 | 535.60 Mn |
| Jun 30, 2022 | 534.20 Mn |
| Mar 31, 2022 | 470.30 Mn |
| Dec 31, 2021 | 564.00 Mn |
| Sep 30, 2021 | 427.00 Mn |